Powder: -20°C for 3 years | In solvent: -80°C for 1 year
KR-39038 is an orally active GRK5 (G protein-coupled receptor kinase 5) inhibitor (IC50: 0.02 μM). KR-39038 inhibits the HDAC5 pathway in neonatal cardiomyocytes and significantly inhibits angiotensin II-induced hypertrophy, resulting in significant anti-myocardial hypertrophy and improved cardiac function. KR-39038 can be used to conduct heart failure studies.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 10-14 weeks | $ 1,520.00 | |
50 mg | 10-14 weeks | $ 1,980.00 | |
100 mg | 10-14 weeks | $ 2,500.00 |
Description | KR-39038 is an orally active GRK5 (G protein-coupled receptor kinase 5) inhibitor (IC50: 0.02 μM). KR-39038 inhibits the HDAC5 pathway in neonatal cardiomyocytes and significantly inhibits angiotensin II-induced hypertrophy, resulting in significant anti-myocardial hypertrophy and improved cardiac function. KR-39038 can be used to conduct heart failure studies. |
Molecular Weight | N/A |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.